Pharming Group N.V. (AMS:PHARM)
Netherlands · Delayed Price · Currency is EUR 0.8480
-0.0122 (-1.42%)
Oct 15, 2026, 3:45 PM CET
Pharming Group Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 600 | 977 | 627 | 690 | 707 | 503 | |
Market Cap Growth | -29.92% | 55.71% | -9.08% | -2.41% | 40.66% | -38.05% |
Enterprise Value | 561 | 947 | 587 | 658 | 657 | 487 |
Last Close Price | 0.86 | 1.43 | 0.93 | 1.03 | 1.08 | 0.78 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 77.66 | 402.37 | - | - | 55.27 | 35.75 |
Forward PE | 51.72 | 60.69 | 60.69 | 170.09 | 28.96 | 16.47 |
PS Ratio | 1.90 | 3.05 | 2.19 | 3.11 | 3.68 | 2.88 |
PB Ratio | 2.57 | 4.14 | 2.94 | 3.49 | 3.69 | 2.96 |
P/TBV Ratio | 4.88 | 8.10 | 4.06 | 5.17 | 5.82 | 5.23 |
P/FCF Ratio | 20.24 | 21.26 | - | - | 35.85 | 21.10 |
P/OCF Ratio | 19.86 | 20.97 | - | - | 33.66 | 15.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.78 | 2.96 | 2.05 | 2.97 | 3.41 | 2.78 |
EV/EBITDA Ratio | 17.51 | 28.07 | 188.69 | - | 40.97 | 18.22 |
EV/EBIT Ratio | 24.89 | 33.94 | - | - | 67.70 | 23.07 |
EV/FCF Ratio | 18.93 | 20.61 | - | - | 33.29 | 20.43 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.42 | 0.42 | 0.51 | 0.78 | 0.82 | 0.84 |
Debt / EBITDA Ratio | 3.12 | 2.69 | 17.02 | - | 8.46 | 4.88 |
Debt / FCF Ratio | 3.30 | 2.15 | - | - | 7.91 | 5.97 |
Net Debt / Equity Ratio | -0.17 | -0.23 | -0.25 | -0.19 | -0.20 | -0.16 |
Net Debt / EBITDA Ratio | -1.37 | -1.60 | -17.24 | 2.74 | -2.37 | -0.99 |
Net Debt / FCF Ratio | -1.31 | -1.17 | 21.50 | 2.24 | -1.93 | -1.11 |
Asset Turnover | 0.80 | 0.84 | 0.69 | 0.55 | 0.50 | 0.49 |
Inventory Turnover | 0.77 | 0.75 | 0.63 | 0.51 | 0.50 | 0.87 |
Quick Ratio | 2.31 | 1.97 | 2.96 | 3.28 | 3.90 | 4.69 |
Current Ratio | 3.01 | 2.59 | 3.77 | 4.06 | 4.65 | 5.33 |
Return on Equity (ROE) | 3.65% | 1.02% | -5.38% | -4.98% | 6.88% | 8.50% |
Return on Assets (ROA) | 3.47% | 4.55% | -0.52% | -3.06% | 1.57% | 3.68% |
Return on Invested Capital (ROIC) | 6.76% | 3.41% | -2.10% | -12.76% | 5.79% | 10.98% |
Return on Capital Employed (ROCE) | 6.80% | 8.50% | -1.10% | -5.70% | 2.80% | 6.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 15, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.34% | 0.25% | -1.82% | -1.38% | 1.81% | 2.80% |
FCF Yield | 4.94% | 4.70% | -0.40% | -2.46% | 2.79% | 4.74% |
Buyback Yield / Dilution | -12.83% | -11.25% | -2.18% | 7.09% | -0.85% | -2.70% |